The focus of the company is the development and provision of tools for the diagnosis and management of substance use and substance use related disorders. As the company grows, these tools will be integrated into the delivery of copyrighted interventions and integrated clinical treatment packages.


The company was founded to serve as a vehicle for the commercial implementation of a set of discoveries made by Drs. Rob Philibert and Anup Madan. Dr. Philibert is a well-known and highly published, NIH trained physician-scientist who is investigating the biological basis for neuropsychiatric illness. Dr. Madan is an accomplished geneticist who hails from the Institute for Systems Biology who has extensive ties in the bio-entrepreneurial community.  In brief, in the first years of the new Millenium, they discovered and published a set of groundbreaking papers that demonstrated that substance use was associated with stable epigenetic changes of DNA.  These findings, suggested that substance use initiated the critical changes in cellular properties which in turn leads to other illnesses were revolutionary and largely flew in the face of the prevailing wisdom that the vulnerability to many complex behavioral disorders was secondary to genetic factors.


Over the next several years, they collaborated extensively and have remained close confidants in the quest to bring these discoveries to clinical translation. At the behest of Dr. Madan, in 2009, Dr. Philibert formed the company to provide a vehicle for the commercialization and evangelization of the technologies. Two years after its creation, Dr. Terry Osborn, an accomplished scientist in his own right with extensive leadership experience in a variety of biotech capacities including  large Pharma (e.g.,Eli Lilly), as well as smaller firms (e.g., Gene Express, Inc.) agreed to serve as President and Chief Executive Officer. After the first initial funding in 2013, he brought in Mr. Michael Levin, an experience financial consultant, to the company as Chief Financial Officer. Together, the four individuals form a potent team for the translation of the scientific findings.


Dr. Rob Philibert is the Chief Executive Officer and the principal founder of Behavioral Diagnostics. Dr. Philibert completed his M.D. and PhD through the University of Iowa Medical Scientist Training Program in 1989.  After finishing his residency in Psychiatry in 1993, he then completed a Pharmacology Research Associate Training Program fellowship and spent nearly 6 focused years of bench top research at the National Institutes of Health in Bethesda, Maryland. Subsequently, he returned to the University of Iowa where he is now a Professor of Psychiatry with adjunct appointments in Genetics, Neuroscience, and Biomedical Engineering.


Dr. Philibert is an accomplished scientist and board certified physician who has an extensive portfolio of grant funding, publications and intellectual property. He and his longtime colleague, Dr. Anup Madan, are the co-inventors of the critical technologies licensed by Behavioral Diagnostics.

Dr. Anup Madan is the second co-founder of Behavioral Diagnostics.  Dr. Madan received his PhD from the Tata Institute of Fundamental Research.  He completed his postdoctoral fellowship under the tutelage of the renowned Dr. Lee Hood of The Institute for Systems Biology (ISB). In 1999, he was promoted to Senior Research Scientist at ISB and remains affiliated with the Institute to the current day.  In 2003, he was appointed to the faculty at the University of Iowa where he met Dr. Philibert and began the process of creating the technologies driving Behavioral Diagnostics.


Dr. Madan has an impressive portfolio of cutting-edge molecular biological publications and extensive intellectual property filings including those associated with Behavioral Diagnostics. He also has extensive experience in both industrial and academic settings at both the national and international level.

Michael R. Levin is the Chief Financial Officer of Behavioral Diagnostics. Mike is a finance executive who has worked in small start ups, established corporations, and management consulting. He has substantial expertise and experience in all aspects of corporate finance (accounting, treasury, internal control, tax, risk management) and corporate strategy. Most recently, Mike serves as CFO of another start-up medical diagnostics company, and as an independent investor and consultant. Previously, he served as a financial executive to a startup in the alternative energy sector, and also as a financial executive for a major energy utility and for an equipment manufacturer. Previously, he spent 18 years as a management consultant with several of the leading global professional services firms. Mike earned his BA and MA in economics from the University of Chicago.

Dr. Terry Osborn is a senior advisor for Behavioral Diagnostics.  Dr. Osborn received his Ph.D. from the University of California, Riverside, and his MBA from Pepperdine University.


Dr. Osborn has spent vast majority of his professional life developing business opportunities, product development and enhancing profitability in startup, growth and turnaround environments. His initial clinical research, manufacturing, distribution and business experience was gained at American Hospital Supply Corporation and Eli Lilly & Company. Since then, he has been involved in critical leadership positions at several  biomedical companies. Dr. Osborn, as Chief Operating Officer, reshaped a new strategic direction for WaferGen Bio-systems, Inc. to take the company public, raising funds for continued product development on the first whole genome/high throughput gene expression real-time PCR and Stem Cell Micro-Incubator platforms. He was Vice President and General Manager at Nichols Institute, an esoteric clinical diagnostic company, where he helped grow revenues from $55 to $300 million. As CEO of the startup company, Gene Express, he led the commercialization and growth activities through the launch of their first “genomic biomarker” product to blue-chip pharmaceutical customers, while concurrently securing new capital funding. Also, as CEO, he led the turnaround of the Pharmaceutical Development Center, a contract formulation, development and cGMP manufacturer of biopharmaceutical and pharmaceutical drugs. During the same time period, he was the co-founder, President and CEO of Health Advance Institute, a national clinical research organization providing clinical research services to pharmaceutical and biotechnology companies.

Dr. Meesha Dogan is a data scientist for Behavioral Diagnostics. She received her PhD in Biomedical Engineering from the University of Iowa. Her expertise bridges medicine and engineering by applying computational techniques on high-throughput biomedical data. Dr. Dogan has co-authored numerous peer-reviewed publications and has applied her data science skills in both academia and industry.


Dr. Dogan is the co-founder and CEO of Cardio Diagnostics, a subsidiary of Behavioral Diagnostics, where she co-invented diagnostic technologies for cardiovascular disease.  Cardio Diagnostics is a pioneer in integrated genetic and epigenetic based tests for precision medicine diagnosis, risk assessment and treatment of cardiovascular disorders. When coupled with artificial intelligence via corporate partners, Cardio Diagnostics will allow primary care practitioners to offer state-of-the-art clinical care by determining each individual’s unique environmental and genetic risk for the top 10 leading causes of death, including coronary heart disease.


Dr. Dogan is also an adjunct assistant professor of Biomedical Engineering at the University of Iowa, where she continues her research efforts to transform medicine towards the precision medicine paradigm.

Dr. Tracy Gunter is a consultant for Behavioral Diagnostics. Dr. Gunter received her M.D. from the University of South Carolina School of Medicine. After completing her residency in psychiatry, she completed a forensics fellowship at the William S. Hall Psychiatric Institute at the University of South Carolina.

Dr. Gunter is an accomplished academician and board certified forensic psychiatrist. She has extensive experience in a variety of academic, community and correctional settings. Currently, she is an Associate Professor of Psychiatry at the Indiana University and holds a variety of adjunct and secondary appointments. She has published extensively with respect to the use of genetic and epigenetic technologies for forensic applications. She is highly sought nationally and internationally as a speaker on the phenomenology and biology of Forensic Psychiatry.

Dr. Cheryl Erwin is a consultant for ethical matters for Behavioral Diagnostics. Dr. Erwin obtained her PhD in medical humanities from University of Texas medical branch at Galveston and her J.D. from the University of Houston. She has written extensively on the business aspects and implementation of healthcare reform. She has extensive experience in medical ethics and has conducted federally funded research on genetic discrimination with respect to neuropsychiatric illnesses.


Currently, Dr. Erwin is the Director of the Center for Healthcare Ethics, Humanities and Spirituality at Texas Tech University Health Sciences Center.